Metabolic and Molecular Mechanisms of NAFLD/NASH

NAFLD/NASH 的代谢和分子机制

• 批准号: 10682156
• 负责人: TERRY L. SHEPPARD
• 金额: $ 1.92万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-15 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10682156
• 关键词: Alberta province; Antidiabetic Drugs; Area; Biological Process; Biology; Biotechnology; Canada; Career Mobility; Clinical; Collaborations; Communities; Data; Dedications; Development; Diabetes Mellitus; Diagnostic; Disease; Education; Educational workshop; Event; Fibrosis; Fostering; Genetic; Goals; Growth; Hepatic; Hepatocyte; Histologic; Industry; Inflammation; Inflammatory; Insulin Resistance; Joints; Knowledge; Learning; Life Style Modification; Lipids; Liver; Liver Fibrosis; Liver diseases; Lobular; Mediator; Medical; Metabolic; Metabolic Diseases; Metabolic syndrome; Methodology; Molecular; Morbidity - disease rate; Obesity; Organ; Outcome; Participant; Pathogenesis; Pathogenicity; Pathway interactions; Pharmacologic Substance; Progressive Disease; Regulation; Research; Research Personnel; Resolution; Role; Scientist; Steatohepatitis; Testing; Therapeutic Agents; Therapeutic Intervention; Thinking; Update; Weight-Loss Drugs; Work; career; clinical practice; design; improved; liver inflammation; liver transplantation; mortality; multidisciplinary; next generation; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; posters; programs; symposium

ABSTRACT Support is requested for a Keystone Symposia conference entitled Metabolic and Molecular Mechanisms of NAFLD/NASH, organized by Drs. James Trevaskis, Jacquelyn Maher and Quentin Anstee. The conference will be held in Banff, Alberta, Canada from March 19 - 23, 2023. Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) represents the hepatic manifestation of the metabolic syndrome and is emerging as a key driver of morbidity and mortality, particularly when present in the context of severe liver fibrosis. The histological hallmarks of NASH including steatosis, lobular inflammation and hepatocyte ballooning are well-characterized; however, while it is widely recognized that NASH is a progressive disease, the pathogenic and molecular mechanisms that initiate and drive NASH remain largely unknown. Therefore, this conference was designed to bring together a broad group of scientific and clinical researchers to highlight and discuss the current evidence exploring the key biological processes involved in NASH and liver fibrosis. This conference program will cover topics such as insulin resistance, hepatocyte lipid management/lipotoxicity and inflammation in the context of steatosis and NASH. Furthermore, advances in our understanding of the molecular and genetic regulation of NAFLD/NASH and the progression to liver fibrosis will also be highlighted. Finally, as NASH is an unmet medical need, this program will integrate the earlier fundamental biology discussion with updates on clinical progress of therapeutic agents, and combinations of agents, for the treatment of NASH and liver fibrosis. Finally, this conference will be held jointly with Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies. The joint conference will focus on the key cellular drivers and mediators of fibrosis in organs beyond the liver and allows for cross-functional discussion and deeper understanding of pathobiology of fibrotic disease. Participants from both conferences will have the opportunity to network through shared sessions, mealtimes, and evening poster sessions.

摘要 要求支持一次题为“代谢和分子机制”的Keystone专题讨论会， NAFLD/NASH，由James Trevaskis，Jacquelyn Maher和Quentin Anstee博士组织。会议 将于2023年3月19日至23日在加拿大阿尔伯塔省班夫举行。 非酒精性脂肪性肝病（NAFLD）和脂肪性肝炎（NASH）代表了肝硬化的肝脏表现。 代谢综合征，并正在成为发病率和死亡率的关键驱动因素，特别是当存在于 严重肝纤维化的背景。NASH的组织学标志包括脂肪变性、小叶性脂肪变性、脂肪变性和脂肪变性。 炎症和肝细胞气球样变是很好的特征;然而，尽管广泛认为， NASH是一种进行性疾病，其致病和分子机制引发和驱动NASH 仍然在很大程度上未知。因此，这次会议旨在汇集一个广泛的科学团体， 和临床研究人员强调和讨论目前的证据探索的关键生物过程 参与NASH和肝纤维化。本次会议计划将涵盖的主题，如胰岛素抵抗， 肝细胞脂质管理/脂肪变性和NASH背景下的脂毒性和炎症。此外，委员会认为， 我们对NAFLD/NASH的分子和遗传调控的理解进展， 肝纤维化也将受到重视。最后，由于NASH是一种未满足的医疗需求，该计划将整合 早期的基础生物学讨论以及治疗药物临床进展的更新，以及 本发明提供了用于治疗NASH和肝纤维化的药剂组合。最后，本次大会将联合 纤维化发病机制和解决：从机制到治疗。联席会议将重点讨论 肝外器官纤维化的关键细胞驱动因子和介质，并允许跨功能 讨论和更深入地了解纤维化疾病的病理生物学。两次会议的与会者 将有机会通过共享会议，用餐时间和晚上的海报会议网络。